Introduction
In contrast to the USA and Europe, where non-ST-segment elevation myocardial infarctions (NSTEMI) are more common than STsegment elevation myocardial infarctions (STEMI) among patients hospitalized with acute myocardial infarction (AMI), [1] [2] [3] [4] [5] [6] China 7-10 and other low-and middle-income countries (LMIC) 11 have a preponderance of STEMI. The explanation for this pattern is not known. The biology and epidemiology of AMI may differ in these countries, or NSTEMI may be under-diagnosed due to a limited availability of biomarker testing or differences in diagnostic approaches. 12 The question of why there is a low rate of NSTEMI is important. If it is because patients with NSTEMI are not identified, then many people may not be receiving appropriate therapies. In that case, improvements in diagnostic practices would be required to improve outcomes. Conversely, if the preponderance of STEMI results from differences in the population, efforts to prioritize STEMI systems of care might have a greater population health impact.
We sought to test the hypothesis that the predominance of STEMI was associated with lower use of biomarkers by evaluating patterns within hospitals. To do so, we used data from a nationally representative sample of patients with AMI during 2001, 2006 , and 2011. We hypothesized that if the low proportion of NSTEMI in China is secondary to the variable use of biomarkers, hospitals with higher rates of biomarker use would have higher proportions of NSTEMI among their patients with AMI. Moreover, we hypothesized that hospitals with specialists and more advanced services would have a much higher NSTEMI proportion.
Methods

Design overview of China PEACERetrospective AMI Study
The design of the China Patient-centered Evaluative Assessment of Cardiac Events Retrospective Study of Acute Myocardial Infarction (China PEACE-Retrospective AMI Study) has been previously described. 13, 14 In brief, the China PEACE-Retrospective AMI Study is a nationally representative sample of hospitalizations for AMI during 2001, 2006 , and 2011 with a two-stage random sampling design. We first stratified our random sample of hospitals by regions and then sampled cases from the selected hospitals. Within hospitals, hospitalizations for AMI were identified using the International Classification of Diseases-Clinical Modification codes versions 9 (421.xx) and 10 (I21.xx), if available, or through principal discharge diagnosis terms. Data abstraction quality was monitored by randomly auditing 5% of the medical records, with overall variable accuracy >98%. The ethics committee of the China National Center for Cardiovascular Diseases approved the study. The study is registered at www.clinicaltrials.gov (NCT01624883).
Study sample
We included all patients with a discharge diagnosis of AMI. The type of AMI, STEMI, or NSTEMI was determined by the diagnosis in the clinical documentation and electrocardiogram (ECG) results. If the local diagnosis was not definitive, cardiologists at the coordinating centre reviewed the medical record and ECG to establish the diagnosis. Left bundle branch block in patients otherwise meeting the diagnosis of AMI was classified as STEMI. The AMI type was further validated by review of electrocardiograms from 300 randomly selected records by a cardiologist not involved in the abstraction (see Supplementary material online, Table S1 ). We excluded discharges in which the patient was transferred in to avoid over counting patients' discharges with AMI, as well as discharges with unknown type of AMI (i.e. neither STEMI nor NSTEMI; n = 73). The study sample profile is outlined in Supplementary material online, Figure S1 .
Variables
The following patient characteristics were collected: demographics, cardiovascular risk factors, medical history, clinical characteristics at admission, and physical examination. The following hospital characteristics were collected: level (secondary and tertiary), location (urban and rural), region (eastern, central, and western), and teaching status. Proportion of troponin use and proportion of any biomarker use [i.e. either creatine kinase (CK), CK-MB, or troponin] were derived from the collected laboratory data based on the patients in the study cohort.
Statistical analysis
To estimate nationally representative rates for each study year, we applied weights proportional to the inverse sampling fraction of hospitals within each stratum and the sampling fraction of patients within each hospital to account for differences in the sampling fraction for each period in all analyses. We calculated the rate of hospital admissions due to STEMI and NSTEMI in China in each study year by estimating the number of patients admitted to hospital for the AMI subtype and dividing by the total population in the corresponding year.
15-17
At a patient level, patient characteristics were compared between AMI types (STEMI and NSTEMI) using v 2 test for categorical variables and analysis of variance for continuous variables. The number [N (%)] in the corresponding groups and P-values for the test of rate difference were reported for categorical variables and mean (standard deviation) in the corresponding groups and P-values for the test of mean difference were reported for continuous variables. Similarly, we compared patient characteristics for NSTEMI patients stratified by proportion of troponin use at the admitting hospital. In addition, the change in proportion of NSTEMI over time overall and stratified by hospital characteristics (level, region, location, teaching status) were calculated and plotted in Figures. In addition, we conducted a hierarchical logistic regression model analysis at a patient level with NSTEMI to determine the association between hospital troponin usage and NSTEMI diagnosis, adjusting for patient demographics, co-morbidities, and hospital characteristics such as admission to rural vs. urban hospital, hospital level, and categories of proportion use of troponin.
At a hospital level, the NSTEMI proportion each year across hospitals stratified by proportion of any biomarker use (0% biomarker use, >0% but <50%, > _50% but <75%, > _75%) and similarly stratified by troponin use was plotted using box-whisker diagrams and were reported using medians and interquartile range (Q1, Q3). Similarly, the NSTEMI proportion across hospitals each year, overall and by level, region, location, teaching status were reported using medians and interquartile range (Q1, Q3). For the hospital-level analysis, we only included hospitals with at least five hospitalizations in a given year. NSTEMI proportion by hospital characteristics and categories of biomarker/troponin use were compared among different years using median scores test in non-parametric analyses.
We also evaluated the relationship of NSTEMI proportion with biomarker/troponin use represented as a continuous variable. We calculated the Pearson's correlation coefficient (R) to evaluate the significance and quantify the strength of the relationship.
All analyses were done using SAS software (version 9.3, SAS Institute, Cary, NC, USA). 
Role of the funding source
The funder of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. The corresponding author has full access to all the data in the study and had final responsibility for the decision to submit for publication. Figure S1 ). Overall, 14.0% patients (N = 2160) had a diagnosis of NSTEMI.
Results
Study sample and baseline characteristics
Baseline characteristics of patients are shown in Table 1 . As compared with patients with STEMI, patients with NSTEMI were older (67.9 years vs. 64.5 years), more likely female (39.8% vs. 29.3%, respectively) and had higher rates of cardiovascular risk factors including hypertension (61.6% vs. 47.2%), diabetes (25.5% vs. 16.1%), and a prior history of angina or CAD (32.7% vs. 20.9%) (P < 0.001 for all). Baseline characteristics of NSTEMI patients stratified by proportion of troponin use at the admitting hospital are shown in the Supplemenatry material online, Appendix Table S2 . Patients admitted to hospitals with higher proportion troponin use had higher rates of hypertension, diabetes, and hyperlipidaemia and were more likely to present with heart failure (Supplementary material online, 
Temporal trends in acute myocardial infarction type
Hospital admissions for both NSTEMI and STEMI increased during the study period. NSTEMI admissions increased 11-fold, from 0. 
Distribution of hospital non-ST-segment elevation myocardial infarction proportion by availability of biomarkers
The proportion of hospitals using any biomarker in > _75% of all AMI cases increased from 64.7% in 2001 to 91.9% in 2011. The proportion of hospitals using troponins in > _75% of all AMI cases increased from 11.0% to 46.6% (both P-value for trend < 0.001). The number of hospitals with at least five AMI cases in any given year increased from 94 in 2001 to 133 in 2006, and 154 in 2011. The distribution of NSTEMI proportion across hospitals stratified by proportional utilization of any biomarker and by troponin use was similar (Figure 2 ). There were no significant differences in NSTEMI proportion by categories of biomarker and troponin use. For instance, in 2011 the median proportion of NSTEMI at hospitals without troponin was 11.2% (4.4-16.7%), similar to those with > _ 75% troponin use (13.0% [8.7-23 .7%]) (P-value for difference 0.77) ( Table 2) .
We assessed the correlation between the NSTEMI proportion at individual hospitals and the proportion of all AMI patients for whom biomarkers were recorded at the hospital. There was no relationship between NSTEMI proportions with biomarker use in all three study years ( Figure 3) . By proportion of troponin use, there was no relationship between NSTEMI proportions with proportion troponin use in 2001 and 2006. In 2011, however, there was a statistically significant, but modest, correlation between NSTEMI proportion and proportion troponin use (R = 0.16, P = 0.043) (Figure 4) .
Hospital non-ST-segment elevation myocardial infarction proportion by hospital characteristics
In 2001 and 2006, the median NSTEMI proportion was similar across sub groups of hospital level, region, location, and teaching status. However, in 2011, the median proportion of NSTEMI (Q1-Q3) in tertiary hospitals (16.6% [10.5-25 .6%]) was higher than at secondary hospitals (10.9% [5.0-17.9%]) (P-value for difference = 0.02) and that at urban hospitals (16.8 [10.5-25.6 ]) was higher than at rural hospitals (10.9 [5.6-17.6]) (P-value for difference = 0.02). Nevertheless, these differences were marginal ( Table 3) . In the multivariate hierarchical logistic regression analysis, after adjusting for patient demographics and comorbidities, the hospital level, location, and proportion troponin use did not predict NSTEMI (see Supplementary material online, Table S3 ).
Discussion
In a nationally representative cohort of patients hospitalized with AMI in China, the proportions of NSTEMI were similarly low at hospitals with low biomarker use, as they were at hospitals with high biomarker use, and STEMI was the predominant phenotype. This pattern of low proportion of NSTEMI was observed across hospital subgroups stratified by level, region, location, and teaching status. Moreover, in a period of marked increase in AMI hospitalizations, the proportion of NSTEMI increased.
The basis of this study is the low observed rate of NSTEMI in China, [7] [8] [9] [10] which is similar to reports from other LMIC, 11 from 51 hospitals (80% tertiary) 20.4% presentations of AMI were NSTEMI. The third study, the Bridging the Gap on CHD Secondary Prevention in China project, 9 conducted in 2006 at 65 sites (a proportionate mix of secondary and tertiary hospitals), in which 20.8% patients had NSTEMI. However, none of these studies by design were nationally representative. The China-PEACE-Retrospective AMI Study, which employed a rigorous random sampling design, is the largest nationally representative sample of hospitalizations with AMI, and thus provides the most robust estimate of NSTEMI prevalence in China. The NSTEMI proportion in our study was noted to be 14%, which is marginally lower but in a similar range as prior studies confirming that indeed there is a low prevalence of NSTEMI in China.
A common explanation offered for this observation is an under diagnosis of NSTEMI in China and other LMICs due to the low use of biomarkers, especially high-sensitivity biomarkers like troponin. Implied support for this argument comes from the fact that the higher proportion of NSTEMI in the West is a relatively recent phenomenon, [2] [3] [4] and the increase in NSTEMI partly occurred during a period Our study is the first to examine if the low proportion of NSTEMI in China is a function of low biomarker use. We found, to the contrary, no significant relationship between NSTEMI proportion and biomarker use, and a low proportion of NSTEMI was seen even in hospitals with a greater use of cardiac biomarkers and sensitive Non-ST-segment elevation myocardial infarction in China biomarkers like troponin, suggesting that higher use of biomarkers did not markedly increase the identification of NSTEMI. When we looked at the data as continuous variables, in 2011, we did find a correlation between troponin usage and NSTEMI proportion which suggests that routine use of sensitive biomarkers like troponin may enhance the sensitivity to diagnose AMI, but the relationship was modest and cannot explain the AMI pattern in China. This is also supported by the fact that hospital factors did not influence NSTEMI proportion, and the low NSTEMI proportion was uniformly observed across strata of hospital level, region, location, and teaching status. In addition, the factors expected to be associated with NSTEMI like advanced age, female sex, hypertension, diabetes, heart failure, and prior CAD were found to be associated with NSTEMI in our sample as well, which indicate a lesser influence of diagnostic tendencies on the observed NSTEMI proportion. 1, 2, [18] [19] [20] If the NSTEMI proportion were influenced by diagnostic tendencies, one would expect these associations to be perturbed. In addition, after adjusting for patient demographics and comorbidities, admission to a tertiary hospital, or in an urban setting, or a hospital with higher proportion troponin use did not predict NSTEMI. These data collectively lend support to the argument that this observed phenomenon of low NSTEMI may in fact represent the true epidemiological pattern of AMI in China rather than a tendency to under-diagnose NSTEMI.
There are several factors that may explain this epidemiologic difference in AMI phenotype between the West and China. Smoking is a major determinant for presenting with STEMI, 21 and rates of smoking in China are 50% higher than in the USA; in males-who are more likely to present with STEMI than females-smoking rates are more than twice as high. 22, 23 In addition, studies suggest that use of preventative therapies like aspirin and statins may reduce the risk of STEMI, 24, 25 which may be another factor for the low STEMI in
Western countries where these medications are widely used. In contrast, rates of statin use in China among patients with occlusive arterial disease are half that observed in the West. 26 Reflecting back on the epidemiologic trend of AMI phenotype in the USA, although the decrease in STEMI and parallel increase in NSTEMI partly occurred during a period of uptake of troponin use, at the same time, this was a period marked by tremendous advancements in therapies for ischemic heart disease, an increasing use of preventative therapies such as aspirin and statin, and declining smoking rates, which can all reduce STEMI risk. 27 This was compounded further by population aging, which increases NSTEMI presentations. 20 In fact, this trend of decreasing STEMI and increasing NSTEMI in the USA was evident even prior to the adoption of troponin testing pointing to a concomitant epidemiologic change in the disease that occurred. 1, 6 Data from our study indicate that an epidemiologic shift may be developing in China as well, given a noticeable increase in the proportion of NSTEMI over time (proportion with NSTEMI more than doubled between 2001 and 2011). A recent hospital discharge database based study from China, although restricted to hospitals in Beijing, showed that proportion of NSTEMI increased from 11.6% in 2006 to 36.2% in 2012. 10 From what we know from the West, this trend of increasing NSTEMI is likely to continue. These results have important implications for China and other countries at a similar point of development. Understanding the pattern and cause of AMI type is critically important to informing the organization of health care delivery to achieve higher quality of care and better outcomes. Although NSTEMI is becoming more common as a proportion of all AMI in China, the current preponderance of STEMI implies that systems of care that can reliably deliver timely reperfusion therapy should be prioritized. Further surveillance of the characteristics of AMI in China over time will be important to future efforts to optimally calibrate the distribution of health resources. An ancillary finding, that many people in China with a diagnosis of AMI do not have biomarkers tested, represents another opportunity for improvement.
Limitations
Our study should be interpreted in the context of certain limitations. First, we studied the hospital level pattern of AMI stratified by biomarker use among patients with a discharge diagnosis of AMI, and not among those presenting with suspected acute coronary syndrome (ACS), which would have truly reflected diagnostic tendencies. However, no such nationally representative data of patients with suspected ACS presenting for medical care exist for China. We hypothesized that hospitals with a higher rate of biomarker and troponin use among diagnosed AMI patients are more likely to have a higher rate of use among those with suspected ACS as well. Second, although we based our analysis on troponin usage and found no significant relationship, the sensitivity threshold of troponin tests can vary between assays and centers may adopt different decision limits which could influence AMI pattern. Third, there are factors that we are unable to assess which could influence our observed pattern of AMI in China. For example, this pattern of low NSTEMI could also represent differential rates of seeking medical care between STEMI and NSTEMI patients.
Conclusions
STEMI is the dominant presentation of AMI in China. We found little evidence that variable biomarker use accounted for this pattern. This suggests that the low proportion of NSTEMI compared to the West may reflect differences in epidemiology rather than only diagnostic tendencies. Focusing on systems of care for STEMI may have an immediate health impact. However, NSTEMI numbers are increasing in China as well and will likely continue to over the next decade, and going forward there is a need to improve screening practices for AMI and standardize approaches. 
